Skip to content

Combined Behavioral/Pharmacological Therapy for Insomnia

Combined Behavioral/Pharmacological Therapy for Insomnia

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00044629
Enrollment
162
Registered
2002-09-05
Start date
2001-09-30
Completion date
2006-08-31
Last updated
2013-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sleep Initiation and Maintenance Disorders

Keywords

Sleep Deprivation, Insomnia, Sleep Disorders

Brief summary

This study will determine how sleeping pills can be combined with nondrug treatments to maximize the benefits of therapy for insomnia.

Detailed description

Long-term insomnia is a common and significant health problem. Two main treatments, pharmacotherapy and behavioral therapy, have been used to help people with insomnia. Because both treatments have advantages and disadvantages, a combination of these treatments may be a good way to treat insomnia. During the first 2 weeks of the study, participants keep a sleep log, wear an actigraph (a device that resembles a wristwatch and records activity to help determine when participants are asleep or awake), and complete questionnaires. Participants are then randomly assigned to receive 6 weeks of behavioral therapy plus zolpidem tartrate (Ambien), behavioral therapy plus placebo, or behavioral therapy alone. During treatment, participants return to the clinic once a week to turn in their sleep logs, download their actigraph, and complete questionnaires. After 6 weeks, participants enter the post-treatment phase of the study, which lasts 2 weeks and is identical to the 2-week assessment at the beginning of the study. After the post-treatment phase, participants enter the follow-up period and are contacted at 3 months, 6 months, and 1 year to complete another 2-week assessment with sleep logs, actigraphy, and questionnaires.

Interventions

DRUGzolpidem tartrate (Ambien)
DRUGPlacebo

Sponsors

National Institute of Mental Health (NIMH)
CollaboratorNIH
Duke University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE

Eligibility

Sex/Gender
ALL
Age
21 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* be between 21 and 75 years of age * have a mean total nocturnal wake time of \> 60 min./night * have a history of insomnia \> 6 months * have a history of one or more poor sleep hygiene practices such as taking 3 or more naps/week, varying bed times or wake times by \> 2 hrs. from day to day, or routinely lying in bed awake for periods \> 30 min

Exclusion criteria

* pregnant women * the terminally ill * individuals with other medical conditions (e.g. chronic pain disorders, etc.) that compromise sleep * individuals with major psychiatric diagnoses * persons with hypnotic-dependent insomnia * subjects on antidepressants or anxiolytics * subjects with evidence of sleep apnea

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026